Chronic obstructive pulmonary disease: AN update on nuclear signaling related to inflammation and anti-inflammatory treatment

Journal of Physiology and Pharmacology

Volumn 59, Issue SUPPL. 6, 2008, Pages 35-42

  Mroz, R M ^a   Holownia, A ^a   Chyczewska, E ^a   Braszko, J J ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

COPD; Glucocorticosteroids; HDAC; Transcription factors

Indexed keywords

CORTICOSTEROID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FORMOTEROL; HISTONE DEACETYLASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; SYNAPTOTAGMIN I; THEOPHYLLINE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR GATA 3; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR;

ANTIINFLAMMATORY ACTIVITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DNA BINDING; DNA DAMAGE; DNA REPLICATION; EPIGENETICS; HUMAN; HYPOTHESIS; ISOMERIZATION; PROTEIN METHYLATION; REVIEW; SUMOYLATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UBIQUITINATION; ANIMAL; CELL NUCLEUS; CHROMATIN; DRUG EFFECT; GENETICS; INFLAMMATION; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; ULTRASTRUCTURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL NUCLEUS; CHROMATIN; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 64549105281     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. www.goldcopd.com/GuidelineResources.asp.l152andl250.
2. Lopez AD, Shibuya K, Rao C et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27: 397-412.
3. Kim WD, Eidelman DH, Izquierdo JL, Ghezzo H, Saetta MP, Cosio MG. Centrilobular and panlobular emphysema in smokers. Two distinct morphologic and functional entities. Am Rev Respir Dis 1991; 144: 1385-1390.
4. Hogg JC, Chu F, Utokaparch S et al. The nature of small airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
5. Drath DB, Larnovsky ML, Huber GL et al. The effects of experimental exposure to tobacco smoke on the oxidative metabolism of alveolar macrophages. J Reticul Soc 1970; 25: 597-604.
6. Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci USA 1964; 51: 786-794.
7. Urnov FD, Wolffe AP. Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene 2001; 20: 2991-3006.
8. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
9. Trotter KW, Archer TK. Nuclear receptors and chromatin remodeling machinery Mol Cell Endocrinol 2007; 265-266: 162-167.
10. Horn PJ, Peterson CL. Heterochromatin assembly: a new twist on an old model Chromosome Res 2006; 14, 83-94.
11. Ito K, Ito M, Elliott WM et al: Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967-1976.
12. Mroz RM, Noparlik J, Chyczewska E, Braszko JJ, Holownia A. Molecular basis of chronic inflammation in lung diseases: new therapeutic approach. J Physiol Pharmacol 2007; 58 Suppl 5: 453-460.
13. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 2001; 293: 1635-1657
14. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-kB determines its association with CBP/p300 or HDAC-1. Mol Cell 2002; 9: 625-636.
15. Barnes PJ, Adcock IM. Transcription factors and asthma. Eur Respir J 1998; 12: 221-234.
16. Barnes PJ. Transcription factors in airway diseases. Lab Invest 2006; 86: 867-872.
17. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
18. Karin M, Liu ZG, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997; 9: 240-246.
19. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2006; 117: 522-543
20. Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroid resistance. Chest 2008; 134; 394-401.
21. Barnes PJ, Ito K, Adcock IM. A mechanism of corticosteroid resistance in COPD: inactivation of histone deacetylase. Lancet 2004; 363: 731-733.
22. Mroz RM, Holownia A, Chyczewska E et al. Cytoplasm-nuclear trafficking of CREB and CREB phosphorylation at Ser133 during therapy of chronic obstructive pulmonary disease. J Physiol Pharmacol 2007; 58 Suppl 5: 437-444.
23. Holownia A, Mroz RM, Noparlik J, Chyczewska E, Braszko JJ. CBP and PAPRy expression during Formoterol or Formoterol and Corticosteroid therapy of COPD. J Physiol Pharmacol 2008 (in press).
24. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004; 200: 689-695.
25. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28: 219-242.